Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

• Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.

• Specifically, two additional cohorts (Cohort C & D) of the single ascending dose portion of the Phase 1 trial in healthy subjects have been completed with no serious adverse events observed.

• No subjects were dropped out of the studies, and no serious adverse events were observed.

• Additionally, no clinically relevant changes regarding vital signs, electrocardiogram, clinical laboratory test results and physical examinations were observed compared to baselines.

• The single ascending dose is still ongoing to gain additional insights into the effect of food on bioavailability and pharmacokinetics.

• On this basis, the company plans to proceed to the multiple ascending dose part in 3Q of 2021.

• In May, the company completed two initial cohorts of the single-dose ascending dose portion of the Phase 1 trial.

• Price Action: APM shares are up 4.64% at $3.16 during the premarket session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Aditxt's COVID-19 Test To Include Specific Antibodies To Detect Individual Immune Response; Shares Rise

• Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.